TOP2/YNL088W Literature Guide Help

Other names published for TOP2: TOR3, TRF3, DNA topoisomerase 2, YNL088W

TOP2 - Mutants/Phenotypes (91)

Results: 61 - 90 of 91 records
   1  2  3  4 
ReferenceOther Genes Addressed
Trigueros S and Roca J  (2001) Circular minichromosomes become highly recombinogenic in topoisomerase-deficient yeast cells. J Biol Chem 276(3):2243-8
Wang H, et al.  (2001) Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation. Biochemistry 40(11):3316-23
Dong J, et al.  (2000) A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons. J Biol Chem 275(11):7980-7
Burden DA and Osheroff N  (1999) In vitro evolution of preferred topoisomerase II DNA cleavage sites. J Biol Chem 274(8):5227-35
Leroy D, et al.  (1999) Mutations in the C-terminal domain of topoisomerase II affect meiotic function and interaction with the casein kinase 2 beta subunit. Mol Cell Biochem 191(1-2):85-95
Liu Q and Wang JC  (1999) Similarity in the catalysis of DNA breakage and rejoining by type IA and IIA DNA topoisomerases. Proc Natl Acad Sci U S A 96(3):881-6
Morris SK, et al.  (1999) Kinetic and thermodynamic analysis of mutant type II DNA topoisomerases that cannot covalently cleave DNA. J Biol Chem 274(6):3446-52
Strumberg D, et al.  (1999) Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions. J Biol Chem 274(40):28246-55
Turnbull RM, et al.  (1999) Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta. Cancer Chemother Pharmacol 44(4):275-82
Wang X, et al.  (1999) The topoisomerase II-associated protein, Pat1p, is required for maintenance of rDNA locus stability in Saccharomyces cerevisiae. Mol Gen Genet 261(4-5):831-40
Wessel I, et al.  (1999) Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. Cancer Res 59(14):3442-50
van Hille B, et al.  (1999) Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds. Br J Cancer 81(5):800-7
Liu Q and Wang JC  (1998) Identification of active site residues in the "GyrA" half of yeast DNA topoisomerase II. J Biol Chem 273(32):20252-60
Nitiss JL, et al.  (1998) The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II. Biochemistry 37(9):3078-85
Reid RJ, et al.  (1998) Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs. Biochim Biophys Acta 1400(1-3):289-300
Sabourin M, et al.  (1998) A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP. J Biol Chem 273(44):29086-92
Benedetti P, et al.  (1997) Study of yeast DNA topoisomerase II and its truncation derivatives by transmission electron microscopy. J Biol Chem 272(18):12132-7
Garinther WI and Schultz MC  (1997) Topoisomerase function during replication-independent chromatin assembly in yeast. Mol Cell Biol 17(7):3520-6
Patel S, et al.  (1997) Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cytotoxicity. Mol Pharmacol 52(4):658-66
Cavalli G, et al.  (1996) Inactivation of topoisomerases affects transcription-dependent chromatin transitions in rDNA but not in a gene transcribed by RNA polymerase II. EMBO J 15(3):590-7
Jensen S, et al.  (1996) Analysis of functional domain organization in DNA topoisomerase II from humans and Saccharomyces cerevisiae. Mol Cell Biol 16(7):3866-77
Elsea SH, et al.  (1995) A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine. J Biol Chem 270(4):1913-20
Froelich-Ammon SJ, et al.  (1995) Increased drug affinity as the mechanistic basis for drug hypersensitivity of a mutant type II topoisomerase. J Biol Chem 270(47):28018-21
Liu YX, et al.  (1994) Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide. Cancer Res 54(11):2943-51
Nitiss JL, et al.  (1994) Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine. Mol Pharmacol 46(4):773-7
Adachi N, et al.  (1992) Characterization of cDNA encoding the mouse DNA topoisomerase II that can complement the budding yeast top2 mutation. Nucleic Acids Res 20(20):5297-303
Gartenberg MR and Wang JC  (1992) Positive supercoiling of DNA greatly diminishes mRNA synthesis in yeast. Proc Natl Acad Sci U S A 89(23):11461-5
Pocklington MJ, et al.  (1990) The effect of novobiocin on yeast topoisomerase type II. Mol Gen Genet 220(2):256-60
Christman MF, et al.  (1988) Mitotic recombination in the rDNA of S. cerevisiae is suppressed by the combined action of DNA topoisomerases I and II. Cell 55(3):413-25
Saavedra RA and Huberman JA  (1986) Both DNA topoisomerases I and II relax 2 micron plasmid DNA in living yeast cells. Cell 45(1):65-70
Results: 61 - 90 of 91 records
   1  2  3  4